Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. [PDF]
Diabetes Obes MetabChen MH +8 more
europepmc +1 more source
Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? [PDF]
World J DiabetesMohammadi S, Al-Harrasi A.
europepmc +1 more source
Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]
BMC Pharmacol ToxicolHayakawa T +5 more
europepmc +1 more source
1,3-disubstituted benzimidazol-2-one derivative as a dipeptidyl peptidase-4 inhibitor
Pavlović Katarina Tomović +5 more
openalex +1 more source
Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial". [PDF]
Diabetes Obes Metabeuropepmc +1 more source
Related searches:
Dipeptidyl peptidase-4 inhibitors
Reactions Weekly, 2021The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire +2 more sources